期刊文献+

人补体受体2-Fc融合蛋白真核表达载体的构建与表达

Construction and expression of a eukaryotic expression vector containing human CR2-Fc fusion protein
下载PDF
导出
摘要 目的构建人补体受体2(CR2)-Fc融合蛋白基因表达载体,在中国仓鼠卵巢细胞(CHO)中表达人CR2-Fc蛋白。方法将人CR2片段和IgG1 Fc片段进行连接,克隆入PCI-neo表达载体。脂质体法将测序正确的重组真核表达载体转染CHO K1细胞进行蛋白表达,采用SDS-PAGE、Western blot法对蛋白表达进行检测和鉴定。结果利用双酶切及基因测序结果证实CR2-Fc基因序列正确,重组真核表达载体构建成功;SDS-PAGE检测纯化产物的相对分子质量(M r)与预期结果一致,Western blot法在同样位置检出条带。结论成功构建了CR2-Fc重组真核表达载体,获得了有活性的融合蛋白。 Objective To construct a eukaryotic expression vector containing human complement receptor 2 (CFI2)-Fc and express the CR2-Fc fusion protein in Chinese hamster ovary (CHO) ceils. Methods The extracellular domain of human CF2 and IgG1 Fc were respectively amplified, ligated and inserted into the eukaryotic expression vector PCI-neo. After verified by restriction enzyme digestion and sequencing, the recombinant plasmid was transfected into CHO K1 cells. The ones with stable expression of the fusion protein were obtained by means of G415 selection. The expression of the CR2-Fc fusion protein was detected and cor^nTed by SDS-PAGE and Western blotting, Results FP_,striction enzyme digestion and sequencing demonstrated that the recombinant plasmid was valid. SDS-PAGE showed that relative molecular mass (Mr) of the purified product was consistent with the expected value. Western blotting further proved the single band at the same position. Coactasion We constructed the eukaryotic expression vector of CR2-Fc/PCI-neo successfully. The obtained fusion protein was active and can be used for the further study of the role in HIV control.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2014年第1期1-3,7,共4页 Chinese Journal of Cellular and Molecular Immunology
基金 国家自然科学基金(81072501)
关键词 补体受体2 补体 蛋白表达 人类免疫缺陷病毒1 complement receptor 2 complement protein expression HIV-]
  • 相关文献

参考文献2

二级参考文献11

  • 1Xuebin Qin,Bin Gao.The Complement System in Liver Diseases[J].Cellular & Molecular Immunology,2006,3(5):333-340. 被引量:20
  • 2[1]Kaplan M.Eculizumab (Alexion)[J].Curr Opin Investig Drugs,2002,3(7):1017-1023. 被引量:1
  • 3[2]Whiss PA.Pexelizumab Alexion[J].Curr Opin Investig Drugs,2002,3(6):870-877. 被引量:1
  • 4[3]Salerno CT,Kulick DM,Yeh CG,et al.A soluble chimeric inhibitor of C3 and C5 convertases,complement activation blocker-2,prolongs graft survival in pig-to-rhesus monkey heart transplantation[J].Xenotransplantation,2002,9(2):125-134. 被引量:1
  • 5[4]Lee JH,Lee HJ,Nahm KM,et al.Effects of combined expression of human complement regulatory proteins and H-transferase on the inhibition of complement-mediated cytolysis in porcine embryonic fibroblasts[J].Transplant Proc,2006,38(5):1618-1621. 被引量:1
  • 6[5]Zhang H,Lu S,Morrison SL,et al.Targeting of functional antibody-decay accelerating factor (DAF) fusion proteins to a cell surface[J].J Biol Chem,2001,276(29):27290-27295. 被引量:1
  • 7[6]Carroll MC.The role of complement in B cell activation and tolerance[J].Adv Immunol,2000,74:61-88. 被引量:1
  • 8[7]Szakonyi G,Guthridge JM,Li D,et al.Structure of complement receptor 2 in complex with its C3d ligand[J].Science,2001,292(5522):1725-1728. 被引量:1
  • 9[8]Harlow E,Lane D.Antibodies:a laboratory manual[M].New York:Cold Spring Harbor Laboratory,1988:726. 被引量:1
  • 10[9]Guthridge JM,Rakstang JK,Young KA,et al.Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg[J].Biochemistry,2001,40(20):5931-5941. 被引量:1

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部